Skip to content

Whole Body PET-MRI in Paediatric and Adolescent Lymphoma

Feasibility of Using Whole Body PET-MRI to Stage and Restage Paediatric and Adolescent Hodgkin Lymphoma - a Pilot Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02935348
Acronym
PET/MRI
Enrollment
25
Registered
2016-10-17
Start date
2014-02-28
Completion date
2017-05-31
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment. Investigators want to investigate if a combined PET-MRI scan could give the same information. Children who join our study will have an extra scan twice during their treatment

Detailed description

Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment. Investigators want to investigate if a combined PET-MRI scan could give the same information. Children who join our study will have an extra scan twice during their treatment Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.

Interventions

Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.

Sponsors

University College, London
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 20 Years
Healthy volunteers
No

Inclusion criteria

1. Suspected or histologically confirmed Hodgkin lymphoma 2. Male or female participants 3. Age 0-20 years inclusive 4. Entered into the EuroNet PHL-C1 trial, LP1 trial or successor Euronet trials, including Euronet PHL C2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial. 5. Participant/Guardian/Parental written informed consent

Exclusion criteria

1. Participants with contraindications to MRI (including cardiac pacemakers or non-MRI compatible intracranial vascular clips) 2. Participants who are pregnant or nursing

Design outcomes

Primary

MeasureTime frame
The investigator will determine the technical feasibility of performing functional co-registered combined PET-MRI in this patient group using diffusion-weighted MR imaging.3 years

Countries

United Kingdom

Contacts

Primary ContactJoey J Clemente
joey.clemente@uclh.nhs.uk02034479094

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026